NYSE:PFE

Pfizer - PFE Stock Forecast, Price & News

$50.73

-0.18 (-0.35%)

(As of 12/5/2022 12:00 AM ET)

Add

Compare

Today's Range: $50.35
▼
$51.03
50-Day Range: $41.75
▼
$51.08
52-Week Range: $41.44
▼
$61.71

Volume: 16.91 million shs
Average Volume: 24.55 million shs
Market Capitalization: $284.76 billion

P/E Ratio: 9.76
Dividend Yield: 3.14%
Price Target: $56.47

Pfizer MarketRank™ Forecast

Analyst Rating: Hold
2.36 Rating Score
Upside/Downside: 11.3% Upside
$56.47 Price Target
Short Interest: Healthy
1.25% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.91
Upright™ Environmental Score
News Sentiment: 0.28
Based on 18 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -24.92%
From $6.46 to $4.85 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.91 out of 5 stars

Medical Sector

27th out of 1,033 stocks

Pharmaceutical Preparations Industry

11th out of 502 stocks

3.2

Analyst's Opinion

Consensus Rating
Pfizer has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 9 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $56.47, Pfizer has a forecasted upside of 11.3% from its current price of $50.73.
Amount of Analyst Coverage
Pfizer has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
1.25% of the outstanding shares of Pfizer have been sold short.
Short Interest Ratio / Days to Cover
Pfizer has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pfizer has recently increased by 28.07%, indicating that investor sentiment is decreasing significantly.

4.2

Dividend Strength

Dividend Yield
Pfizer pays a meaningful dividend of 3.14%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Pfizer has been increasing its dividend for 11 years.
Dividend Coverage
The dividend payout ratio of Pfizer is 30.77%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Pfizer will have a dividend payout ratio of 32.99% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Pfizer has received a 67.54% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Covid-19 vaccines", "Pneumococcal vaccines", and "Apixaban" products. See details.
Environmental Sustainability
The Environmental Impact score for Pfizer is -1.91.

1.3

News and Social Media Coverage

News Sentiment
Pfizer has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 18 news articles for Pfizer this week, compared to 22 articles on an average week.
Search Interest
Only 190 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.
MarketBeat Follows
Only 63 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is a decrease of -28% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pfizer insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.05% of the stock of Pfizer is held by insiders.
Percentage Held by Institutions
67.90% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Pfizer are expected to decrease by -24.92% in the coming year, from $6.46 to $4.85 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pfizer is 9.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.73.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pfizer is 9.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.96.
Price to Earnings Growth Ratio
Pfizer has a PEG Ratio of 0.88. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Pfizer has a P/B Ratio of 3.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Pfizer (NYSE:PFE) Stock

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

PFE Stock News Headlines

December 5, 2022 | marketbeat.com

Pfizer asks FDA to clear updated COVID shot for kids under 5

Pfizer is asking U.S. regulators to authorize its updated COVID-19 vaccine for children under age 5

December 2, 2022 | marketbeat.com

Asian shares sink on revived worries over recession, China

Shares have retreated in Asia after a mixed day on Wall Street

November 30, 2022 | marketbeat.com

Cosmos Holdings May be a Long-Term Buy with Short-Term Risk (PFE)

Cosmos Holdings stock is up 618% in November likely due to a short squeeze. This article explains why Cosmos Holdings may still be a good long-term investment

November 30, 2022 | marketbeat.com

Chinese vaccine plans spark hope for end of 'zero COVID'

A campaign to vaccinate older Chinese has sparked hopes Beijing might roll back severe anti-virus controls that prompted angry protesters to demand President Xi Jinping resign

November 18, 2022 | marketbeat.com

Pfizer booster spurs immune response to new omicron subtypes

Pfizer said its updated COVID-19 booster may offer some protection against newly emerging omicron mutants even though it’s not an exact match

November 16, 2022 | marketbeat.com

Four Healthcare Stocks To Watch This Week (PFE)

Healthcare has long been a wise investment, as the industry consistently grows yearly. Some analysts believe that trend will continue.

November 16, 2022 | marketbeat.com

Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market? (PFE)

Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry.

November 7, 2022 | marketbeat.com

BioNTech earnings drop but forecast for vaccine income grows

BioNTech, which teamed with Pfizer to develop a powerful COVID-19 vaccine, has reported that third-quarter earnings are close to half what they were a year earlier